SMG9

Across TCGA pan-cancer cohorts, SMG9 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SMG9 data layer compared with 23 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in rectum adenocarcinoma (READ), where higher SMG9 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SMG9 expression acts as an unfavorable survival marker, although some lineages such as LUSC show a favorable association.

READ, SKCM, and PRAD are the cancer types where SMG9 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
READ	DFS	Median	All	0.182	0.819	.004	18	view →
SKCM	OS	Median	III,IV	0.230	0.721	.004	9	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
STAD	OS	Median	All	0.250	0.729	.028	6	view →
BRCA	DFS	Median	All	0.294	0.903	<.001	6	view →
LUSC	DFS	Median	All	1.000	0.387	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SMG9–READ (DFS)

Open the READ breakdown →